301267 Huaxia Eye Hospital Group
- 25.49
- +0.38+1.51%
Huaxia Eye Hospital Group News
Huaxia Ophthalmology (301267): Steady growth in performance, acceleration of epitaxial mergers and acquisitions
Description of the incident on April 25, the company released the 2023 annual report and the 2024 quarterly report: the company's revenue in 2023 was 4,013 billion yuan, up 24.12% year on year; net profit to mother was 666 million yuan, the same
Huaxia Ophthalmology (301267): Dominant disciplines lead growth, and the implementation of epitaxial mergers and acquisitions is expected to increase annual performance
Note: On April 25, the company released its 23 annual report and 24 quarterly report. The company's revenue in '23 was 4,013 billion yuan (+24.12%), net profit to mother was 666 million yuan (+29.60%), deducted
Huaxia Ophthalmology (301267): Performance is in line with expectations, and epitaxial mergers and acquisitions are about to be implemented
Maintain an increase in holdings rating. Considering the recovery in consumer medicine and the pace of implementation of hospital mergers and acquisitions, the 2024-2025 EPS forecast was lowered to 0.94/1.07 yuan (originally 1.14/1.48 yuan), and the forecast for 2026
Huaxia Ophthalmology (301267): In-vitro hospital integration and implementation continues to improve the national layout
Event: On April 25, 2024, Huaxia Ophthalmology released the 2023 Report and 24Q1 Report. In 2023, the company achieved revenue of 4,013 billion yuan (+24.12%) and net profit of 666 million yuan (+30) to mother
Express News | Sinqi Eye Medicine: Aier Eye Hospital Group and others have reached a cooperation with the company and will introduce low-concentration atropine in the near future
Huaxia Ophthalmology (301267): The 24Q1 performance growth rate has slowed, and the implementation of mergers and acquisitions is expected to increase annual results
Core view: Huaxia Ophthalmology announced the 2023 and 2024Q1 results. The company achieved operating income of 4,013 billion yuan in 2023, +24.12% year-on-year; net profit to mother was 666 million yuan, +29 million yuan year-on-year.
Huaxia Ophthalmology (301267): Steady growth in performance, endogenous extension improving national layout
Investment highlights The 2023 performance grew rapidly, and the overall performance was stable in 2024Q1. The company released the 2023 report and the 2024 quarterly report: it achieved revenue of 4,013 billion yuan and net profit to mother of 666 million yuan for the full year of 2023, compared with the same period last year
Huaxia Ophthalmology (301267): The 24Q1 results are in line with expectations and the acquisition of hospitals will increase performance
Incident: The company announced that in 2023, it achieved revenue of 4,013 billion yuan (+24.12%, indicating year-on-year growth rate, same below), net profit to mother of 666 million yuan (+29.60%), after deducting 6.62 billion yuan in net profit not attributable to mother
Huaxia Ophthalmology (301267): 1Q24 steady growth service network continues to expand
Against the backdrop of internal and external factors, 1Q24's performance grew steadily, and the company achieved revenue/net profit of 40.1/670 million yuan in 23 years (yoy +24.1%/+29.6%), and 1Q24 achieved revenue/net profit to mother
Dongguan Securities released a research report on April 25 stating that Huaxia Ophthalmology (301267.SZ) was given a purchase rating. The main reasons for the rating include: 1) the core business has maintained rapid growth; 2) all domestic regions have a
Dongguan Securities released a research report on April 25 stating that Huaxia Ophthalmology (301267.SZ) was given a purchase rating. The main reasons for the rating include: 1) the core business has maintained rapid growth; 2) all domestic regions have achieved relatively rapid positive revenue growth; 3) gross margin has continued to rise. (Mainichi Keizai Shimbun)
Huaxia Ophthalmology (301267.SZ): Net profit of 156 million yuan in the first quarter increased 3.75% year on year
Gelonghui, April 26 | Huaxia Ophthalmology (301267.SZ) released its report for the first quarter of 2024. Operating revenue for the reporting period was 978 million yuan, up 5.09% year on year; net profit attributable to shareholders of listed companies was 156 million yuan, up 3.75% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 157 million yuan, up 6.89% year on year; basic earnings per share were 0.19 yuan.
Huaxia Ophthalmology (301267): Continuing to advance the “endogenous growth+epitaxial merger and acquisition” strategy
Incident: The company released its 2023 report and 2024 quarterly report. In 2023, the company achieved total revenue of 4,013 billion yuan, an increase of 24.12% over the previous year; achieved net profit of 666 million yuan to mother, an increase of 29.6 million yuan over the previous year
Huaxia Ophthalmology (301267.SZ) has repurchased a total of 5.2251 million shares at a cost of 151 million yuan
Huaxia Ophthalmology (301267.SZ) announced that as of February 29, 2024, the company is using centralized bidding transactions...
Huaxia Ophthalmology (301267): From coastal to inland, the prospects for the national layout are improving
Report Summary: Huaxia Ophthalmology uses a national chain as the layout, adheres to the development strategy of “endogenous growth+epitaxial mergers and acquisitions”, focuses on developing high-potential high-quality markets, and continues to expand from coastal to inland. Huaxia Ophthalmology is about to enter the second round of rapid expansion. Business
Huaxia Ophthalmology (301267.SZ) has repurchased a total of 3.788 million shares at a cost of 111 million yuan
Huaxia Ophthalmology (301267.SZ) announced that as of January 31, 2024, the company is using centralized bidding transactions...
Huaxia Ophthalmology (301267.SZ): We have established long-term and stable cooperative relationships with major ophthalmic medical device manufacturers at home and abroad
Gelonghui January 31 丨 An investor asked Huaxia Ophthalmology (301267.SZ) on the investor interactive platform, “What ophthalmic medical device products has the company laid out?” The company replied that the company has established long-term and stable cooperative relationships with major ophthalmic medical device manufacturers at home and abroad, and has actively introduced cutting-edge international ophthalmology diagnosis and treatment technologies and products to provide comprehensive, diverse and personalized diagnosis and treatment services for patients with eye diseases.
Huaxia Ophthalmology (301267): Steady increase in revenue and profit, balanced development of consumer medicine and serious medical care
Performance has grown steadily, and revenue and profit have maintained a high growth rate. The company achieved revenue of 3.103 billion yuan in the first three quarters of 2023, a year-on-year increase of 22.98%, and net profit to mother of 557 million yuan, an increase of 40.17% year-on-year, after deducting non-return to mother
Huaxia Ophthalmology (301267.SZ): Initial repurchase of 687,700 shares involving 20037,800 yuan
Gelonghui, January 22丨Huaxia Ophthalmology (301267.SZ) announced that on January 22, 2024, for the first time, the company repurchased 687,700 shares of the company's shares through a dedicated securities account, accounting for 0.08% of the company's current total share capital. The highest transaction price was 29.70 yuan/share, the minimum transaction price was 28.57 yuan/share, and the total amount paid was 200377.89 million yuan (not including transaction fees).
Huaxia Ophthalmology (301267.SZ): Under the two-wheel drive of “comprehensive eye diseases+consumer medicine”, we strive to achieve the annual performance growth target of 30% or more
Gelonghui, January 16 | Huaxia Ophthalmology (301267.SZ) said on the interactive platform that as a leading ophthalmology chain group in China, the company has outstanding clinical diagnosis and treatment capabilities and large-scale hospital chain management capabilities, and has a certain first-mover advantage and scale effect, leading the industry in various dimensions such as annual number of patients, ophthalmology surgery volume, and revenue; the company is centered on core hospitals with strong diagnosis and treatment capabilities to promote the continuous improvement of the Group's general diagnosis and treatment service system, hospital management and discipline construction; the company has brought together a large number of top experts in the industry to continue to build Department A highland of talent development and diagnosis and treatment technology
Huaxia Ophthalmology (301267.SZ): Plans to spend 150 million yuan to 250 million yuan to buy back the company's shares
Gelonghui, January 8 | Huaxia Ophthalmology (301267.SZ) announced that the company plans to use its own funds to repurchase some of the company's shares through centralized bidding transactions to implement employee stock ownership plans or equity incentives. The total repurchase capital is not less than 150 million yuan and no more than 250 million yuan (all including capital). The repurchase price range does not exceed RMB 50.93 per share. Based on the upper limit of the total repurchase capital of 250 million yuan and the upper limit of the repurchase price of 50.93 yuan/share, the estimated number of shares to be repurchased is approximately 49,086.98 million shares, accounting for about 0.58% of the company's current total share capital; according to the lower limit of the total repurchase amount 1
Analysis
Price Target
No Data
